Eszopiclone: A novel cyclopyrrolone with potential benefit in both transient and chronic insomnia

Formulary

Volumn 38, Issue 10, 2003, Pages 582-593

  Mack, Alicia ^a   Salazar, J Octavio ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; ESZOPICLONE; HYPNOTIC AGENT; PYRROLE DERIVATIVE; SEPRACOR; UNCLASSIFIED DRUG; ZOPICLONE;

BITTER TASTE; CHRONIC DISEASE; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; INSOMNIA; REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TASTE DISORDER; UNITED STATES; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 0141919756     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Roth T, Hajak G, Ustun TB. Consensus for the pharmacological management of insomnia in the mew millenium. IJOP. 2001;55(1):42-52.
2. Central nervous system agents page. Available at:http://www.sepracor.com/science/index.cfm?s=2A. Accessed August 20, 2003.
3. Roehrs T, Roth T. Hypnotics: An update. Curr Neurol Neurosci Rep. 2003;3:181-184.
4. Hesse LM, Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem, and zaleplon. CNS Drugs. 2003;17(7):513-532.
5. Giovanni Terzano M, Rossi M, Palomba V. New drugs for insomnia. Comparative tolerability of zopiclone, zolpidem, and zaleplon. Drug Safety. 2003;26(4):261-282.
6. Georgiev V. (S)-Zopiclone. Curr Opin Invest Drugs. 2001;2(2):271-273.
7. Blaschke G, Hempel G, Muller WE. Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site. Chirality. 1993;5:419-421.
8. Fernandez C, Martin C, Gimenez F, and Farinotti R. Clinical pharmacokinetics of zopiclone. Clin Pharmacokinet. 1995;29(6):431-441
9. Leese P, Maier G, Vaickus L, et. Al. Eszopiclone: Pharmacokinetic and pharmacodynamic effects of a novel sedative hypnotic after daytime administration in healthy subjects. Sleep. 2003. 26(Suppl):061.C. Abstract.
10. Zammit GK, Gillan JC, McNabb L, et. Al. Eszopiclone: A novel non-benzodiazepine anti-insomnia agent: A six-week efficacy and safety study in adult patients with chronic insomnia. Sleep. 2003. 26(Suppl):0747.L. Abstract.
11. Rosenberg RP, Jamieson A, Vaickus L, et. Al. Eszopiclone: A Novel non-benzodiazepine sedative-hypnotic: Efficacy and safety in a model of transient insomnia. Sleep. 2003. 26(Suppl):093.L. Abstract.
12. Krystal A, Walsh J, Roth T, et al. The sustained efficacy and safety of eszopiclone over six months of nightly treatment: A placebo controlled study in patients with chronic insomnia. Sleep. 2003;26(Suppl):0779.L. Abstract.
13. Eszopiclone (Estorra) fact page. Available at: http://sepracor.com/science/print.cfm?s=2A. Accessed August 20, 2003.
14. Jonas JM, Coleman BS, Sheridan AQ. Comparative Clinical Profiles of Triazolam Versus Other Short-Acting Hypnotics. J Clin Psych. 1992;53:12(suppl)19-33.